Aptevo Therapeutics Inc.
- APVO
- NASDAQ
- Biotechnology
- Bispecific Antibody (Oncology)
$1.62
Today −0.34%Quote Oct 19, 2026, 04:53 PM UTC
−11.96%over the last month
Max drawdown −15.2%From 1-month high −15.2%3 months −66.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Aptevo Therapeutics
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
33
Founded
2016
Market value
$2.9M
Quote Oct 19
Floor
$1.55
4.3% below price
Resistance
$1.65
1.9% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about APVOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free